Annexon, Inc.

XNASHealth care

Last traded price · USD

$4.33

+3.34%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 05:55 IST · A quote does not mean the product is available to trade on your account.

Day's open: $4.26
Previous close: $4.19
Volume: 4.5M
Day's high: $4.52
Day's low: $4.16

In brief

Annexon, Inc. is a health care company listed on Nasdaq, valued at about $821M.
Its shares closed at $4.33 on 4 Nov 2026, up 40.6% over the past year.
From India you can buy ANNX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Annexon, Inc. (ANNX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ANNX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ANNX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +7.4% (SPY −1.6%, XLV +13.5%). 3 months: −19.4% (SPY −0.4%, XLV +15.5%). 1 year: +40.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ANNX, SPY and XLV · as of 4 Nov 2026
10.3 days to cover short interest
31.6M shares were sold short at the 15 Oct 2026 settlement, 16.7% of the 189.6M shares outstanding; covering them would take 10.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $4.33 was 4.4% above its 50-day average ($4.15) and 16.6% below its 200-day average ($5.19). It has closed below the 200-day for 54 sessions, since 20 Aug 2026. The 50-day average crossed below the 200-day on 4 Sep 2026, 42 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
39% of the way up its 52-week range
Closed at $4.33 on 4 Nov 2026: 39.7% below the 52-week high of $7.18 (23 Jan 2026) and 70.5% above the low of $2.54 (13 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+7.4%

6 months−24.0%

1 year+40.6%

5 years−73.6%

Newswire

About

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Website

Notable moves

May 26, 2023
+35.71%
May 25, 2023
−59.38%
January 5, 2022
−34.06%

Newswire

About

Website

Notable moves

May 26, 2023
+35.71%
May 25, 2023
−59.38%
January 5, 2022
−34.06%

Annexon, Inc.

XNASHealth care

Last traded price · USD

$4.33

+3.34%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 05:55 IST · A quote does not mean the product is available to trade on your account.

Day's open: $4.26
Previous close: $4.19
Volume: 4.5M
Day's high: $4.52
Day's low: $4.16

In brief

Annexon, Inc. is a health care company listed on Nasdaq, valued at about $821M.
Its shares closed at $4.33 on 4 Nov 2026, up 40.6% over the past year.
From India you can buy ANNX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Annexon, Inc. (ANNX) shares from India?

Do I need the price of a whole ANNX share to invest?

How much can I invest in US stocks in a year?

Can I trade ANNX options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +7.4% (SPY −1.6%, XLV +13.5%). 3 months: −19.4% (SPY −0.4%, XLV +15.5%). 1 year: +40.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ANNX, SPY and XLV · as of 4 Nov 2026
10.3 days to cover short interest
31.6M shares were sold short at the 15 Oct 2026 settlement, 16.7% of the 189.6M shares outstanding; covering them would take 10.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $4.33 was 4.4% above its 50-day average ($4.15) and 16.6% below its 200-day average ($5.19). It has closed below the 200-day for 54 sessions, since 20 Aug 2026. The 50-day average crossed below the 200-day on 4 Sep 2026, 42 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
39% of the way up its 52-week range
Closed at $4.33 on 4 Nov 2026: 39.7% below the 52-week high of $7.18 (23 Jan 2026) and 70.5% above the low of $2.54 (13 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+7.4%

6 months−24.0%

1 year+40.6%

5 years−73.6%

Newswire

About

Website

Notable moves

May 26, 2023
+35.71%
May 25, 2023
−59.38%
January 5, 2022
−34.06%

Newswire

About

Website

Notable moves

May 26, 2023
+35.71%
May 25, 2023
−59.38%
January 5, 2022
−34.06%

Annexon, Inc.

Annexon, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

10.3 days to cover short interest

Above its 50-day average, below its 200-day

39% of the way up its 52-week range

Annexon, Inc.

Annexon, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

10.3 days to cover short interest

Above its 50-day average, below its 200-day

39% of the way up its 52-week range